Table 3. Univariate survival analysis: significant survival predictors in the study group.
| Variable | Hazard Ratio | |
| (95% CI) | p Value | |
| Nodule size>3,5 cm | 1,28 (1,00–1,65) | 0,0461 |
| Multinodular | 1,31 (1,01–1,70) | 0,0373 |
| Macroscopic vascular invasion | 4,01 (2,42–6,57) | <0,0001 |
| Grading | ||
| Moderately versus well differentiated | 2,88 (1,53–5,73) | <0,0001 |
| Poorly versus moderately differentiated | 2,40 (1,36–4,16) | |
| AFP mRNA positive | 3,22 (1,97–5,33) | <0,0001 |
| VEGF>23 pg ml−1 | 2,37 (1,45–3,87) | 0,0007 |
| AFP mRNA/VEGF (3 stages) | ||
| − + or + − versus − − | 2,21 (1,20–4,08) | <0,0001 |
| + + versus − + or + − | 2,31 (1,28–4,20) | |
| AFP mRNA/VEGF (4 stages) | ||
| −+ versus − − | 1,78 (0,74–3,90) | <0,0001 |
| +− versus −+ | 1,56 (0,69–3,85) | |
| ++ versus +− | 1,79 (0,94–3,50) | |
| Bilobar | 1,74 (1,01–2,92) | 0,0479 |
| Child-Pugh B–C | 1,40 (1,09–1,80) | 0,0076 |
| Surgery | 1,64 (1,28–2,13) | 0,0001 |
| PST>1 | 4,12 (2,37–6,93) | <0,0001 |
| TNM | ||
| III versus I–II | 1,91 (0,94–3,78) | <0,0001 |
| IV versus III | 2,55 (1,38–4,97) | |
| BCLC | ||
| B versus A | 2,04 (1,00–4,15) | <0,0001 |
| C–D versus B | 3,52 (1,94–6,71) |
AFP mRNA/VEGF (3 stages): stage 1 = − −, stage 2 = − + or + −, stage 3 = + +.
AFP mRNA/VEGF (4 stages): stage 1 = − −, stage 2 = − +, stage 3 = + −, stage 4 = + +.